| Literature DB >> 35352776 |
Danielle Lazarin-Bidóia1, Francielle Pelegrin Garcia1, Tânia Ueda-Nakamura1, Sueli de Oliveira Silva1, Celso Vataru Nakamura1.
Abstract
Over the past years, natural products have been explored in order to find biological active substances to treat various diseases. Regarding their potential action against parasites such as trypanosomatids, specially Trypanosoma cruzi and Leishmania spp., much advance has been achieved. Extracts and purified molecules of several species from genera Piper, Tanacetum, Porophyllum, and Copaifera have been widely investigated by our research group and exhibited interesting antitrypanosomal and antileishmanial activities. These natural compounds affected different structures in parasites, and we believe that the mitochondrion is a strategic target to induce parasite death. Considering that these trypanosomatids have a unique mitochondrion, this cellular target has been extensively studied aiming to find more selective drugs, since the current treatment of these neglected tropical diseases has some challenges such as high toxicity and prolonged treatment time. Here, we summarise some results obtained with natural products from our research group and we further highlighted some strategies that must be considered to finally develop an effective chemotherapeutic agent against these parasites.Entities:
Mesh:
Year: 2022 PMID: 35352776 PMCID: PMC8970591 DOI: 10.1590/0074-02760220396
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743
Summary of major natural products evaluated by our research group against trypanosomatids
| Species | Evaluated material | Activity | References | ||||
|
|
| ||||||
| epimastigote | trypomastigote | amastigote | promastigote | amastigote | |||
|
| hydroalcoholic extract | 39.8a* 9.4a* 65.8a* 79.5a* 26.0a* 34.3a* 36.5a* 95.0a* 49.5a* 28.3a* 89.7a* 5.9a* 15.6a* 11.2a* 13.8a* 9.3a* 51.9a* 93.0a* 95.5a* | - - - - - - - - - - - - - - - - - - | - - - - - - - - - - - - - - - - - - | 11.6a* 5.4a* 58.3a* 98.0a* 5.1a* 38.0a* 8.5a* 98.1a* 52.5a* 54.7a* 98.2a* 42.2a* 65.4a* 69.1a* 65.7a* 4.3a* 36.5a* 96.5a* 96.4a* | 48.2a* 32.3a* 64.6a* 95.2a* 28.4a* 51.6a* 57.5a* 92.7a* 97.5a* 91.5a* 96.8a* 90.0a* 52.0a* 9.1a* 54.9a* 18.1a* 21.0a* 94.3a* 99.0a* |
|
|
| eupomatenoid-3 eupomatenoid-5 eupomatenoid-6 conocarpan | 26.3b* 7.0b* 7.5b* 8.0b* | - - - - | - - - - | - - - - | - - - - |
|
|
| eupomatenoid-5 | - | - | 5.0b+ | - | - |
|
|
| eupomatenoid-5 | - | 40.5c# | - | - | - |
|
|
| eupomatenoid-5 | - | - | - | 9.0b+ | 5.0b$ |
|
|
| aqueous extract ethanolic extract ethyl-acetate extract hexane fraction dichloromethane fraction ethyl-acetate fraction methanol fraction parthenolide | 280.0b* 3.0b* 50.0b* 2.1b* 2.1b* 79.0b* 40.0b* 0.5b* | - - - - - - - - | - - - - - - - 51.0d* | - - - - - - - - | - - - - - - - - |
|
|
| guaianolide | 18.1c* | 5.7c$ | 66.6c* | - | - |
|
|
| aqueous extract ethanolic extract hexane extract ethyl-acetate extract dichloromethane fraction hexane fraction ethyl-acetate fraction methanol fraction | - - - - - - - - | - - - - - - - - | - - - - - - - - | 490.0b& 434.0b& 409.0b& 29.0b& 3.6b& 7.0b& 43.1b& 43.8b& | 74.8b& 36.7b& 42.4b& <10b& 2.7b& 2.9b& 28.3b& 48.4b& |
|
|
| parthenolide | - | - | - | 0.37b& | 0.81b& |
|
|
| dichloromethane extract dichloromethane fraction compound A compound B | - - - - | - - - - | - - - - | 60.3b+ 57.5b+ 7.7b+ 21.3b+ | 77.7b+ 72.5b+ 19.0b+ 28.7b+ |
|
|
| hydroethanolic extract petroleum ether fraction hexane fraction chloroform fraction dichloromethane fraction ethyl-acetate fraction pheophorbide A | 213.8b* 689.0b* 213.3b* 204.7b* 184.7b* 556.7b* >100b* | 24.8b$ >100b$ 24.0b$ 19.8b$ 16.2b$ 66.7b$ 2.3b$ | >100b* - - 13.7b* - - 2.3b* | - - - - - - - | - - - - - - - |
|
|
| copaiba oil | - | - | - | 5.0b+ | 20.0b+ |
|
|
| copaíba oil | - | - | - | - | 100.0e |
|
|
| agathic acid hydroxycopalic acid kaurenoic acid methyl copalate pinifolic acid polyaltic acid | - - - - - - | - - - - - - | - - - - - - | 28.0b+ 2.5b+ 28.0b+ 6.0b+ 70.0b+ 35.0b+ | 17.0b+ 18.0b+ 3.5b+ 14.0b+ 4.0b+ 15.0b+ |
|
|
| methyl copalate acid copalic acid 3β-hydroxycopalic acid agathic acid pinifolic acid polyaltic acid kaurenoic acid β-caryophylene | 83.3c* 42.7c* 41.2c* 86.8c* 85.4c* 167.7c* 167.2c* 78.4c* | 377.3c$ 444.0c$ 453.1c$ 823.3c$ 163.0c$ 965.1c$ 596.0c$ 1,593.0c$ | 2.5c* 1.3c* 1.8c* 14.9c* 18.6c* 28.4c* 16.5c* 63.7c* | - - - - - - - - | - - - - - - - - |
|
|
| copaiba oil | 17.0b* 19.0b* 35.0b* 18.5b* 30.5b* 19.0b* 21.5b* 51.0b* | 285.0b$ 97.5b$ 210.0b$ 182.5b$ 175.0b$ 242.5b$ 110.0b$ 215.0b$ | <5.0b* <5.0b* 7.3b* <5.0b* 7.7b* <5.0b* <5.0b* 10.0b* | - - - - - - - - | - - - - - - - - |
|
Treatment time: (#) 2 h, ($) 24 h, (&) 48 h, (+) 72 h, (*) 96 h, (-) not evaluated; a: % growth inhibition in 100 μg/mL; b: concentration in μg/mL able to cause lysis or inhibit growth of 50% of the cells; c: concentration in μM able to cause lysis or inhibit growth of 50% of the cells; d: % growth inhibition in 2 μg/mL; e: reduction in the average lesion size of infected BALB/c mice.
Summary of alterations in trypanosomatids induced by natural products evaluated by our research group
| Species | Protozoa | Alterations | References |
| Eupomatenoid-5 from |
| SEM: rounded and deformed cells TEM: mitochondrial swelling, kinetoplast alteration, myelin-like figures, multinucleation |
|
|
| TEM: cytoplasmic vacuolisation, autophagic vacuoles | ||
| Eupomatenoid-5 from |
| FC: depolarisation of the mitochondrial membrane SA: lipid peroxidation, increased glucose-6-phosphate dehydrogenase, increase in H2O2 consumption |
|
|
| SEM: plasma membrane damage with leakage of cytoplasmic contents TEM: plasma membrane detachment, cytoplasmic vacuolisation FC: depolarisation of the mitochondrial membrane SA: lipid peroxidation | ||
| Eupomatenoid-5 from |
| FM: DNA fragmentation, autophagic vacuoles FC: depolarisation of the mitochondrial membrane, cell membrane disruption, increase in ROS/RNS production, phosphatidylserine exposure, decrease in cell volume SA: increase in mitochondrial O2•− production, decrease in total reduced thiol levels, lipid peroxidation |
|
| Eupomatenoid-5 from |
| TEM: mitochondrial swelling, autophagic vacuoles, vesicles located in the flagellar pocket, myelin-like figures |
|
| Eupomatenoid-5 from |
| SEM: reduction and rounding of the cellular body FC: depolarisation of the mitochondrial membrane, phosphatidylserine exposure, decrease in cell volume, plasma membrane disruption, G0/G1 phase cell cycle arrest SA: increase in mitochondrial O2•− production, increased total ROS production, decrease in total reduced thiol levels |
|
| Parthenolide from |
| SEM: distortion and decrease of the cell body and flagellum length TEM: mitochondrial swelling, multinuclear cells, increase of reservosomes, autophagic vacuoles, concentric structures, myelin-like figures, rearrangement of internal membranes |
|
| Parthenolide from |
| SEM: rounding and shortening of the parasite, loss of integrity of the plasma membrane |
|
| Guaianolide from |
| SEM: thinning and stretching of the cell body and flagellum TEM: presence of membranes that involved organelles, myelin-like figures FC: cell volume reduction, decrease in mitochondrial membrane potential |
|
|
| SEM: rounding and shortening of the parasite with leakage of cytoplasmic contents | ||
| Parthenolide from |
| TEM: vesicles located in the flagellar pocket, structures similar to large lysosomes |
|
| Compound A and B from |
| SEM: rounded and swollen cells TEM: mitochondrial swelling FC: decrease in mitochondrial membrane potential |
|
| Pheophorbide A from |
| SEM: rounding and shortening of the parasite body TEM: mitochondrial swelling, autophagic vacuoles, concentric membrane structures, abnormal chromatin distribution nuclear |
|
|
| SEM: rounding of the parasite, plasma membrane damage | ||
| Copaiba oil from |
| SEM: rounded shape with two flagella, protein denaturation of the cell surface TEM: mitochondrial swelling, vesicles located in the flagellar pocket, cytoplasmic vacuolisation |
|
|
| SEM: rupture of the plasma membrane with loss of their contents, protein denaturation of the cell surface TEM: mitochondrial swelling, vesicles located in the flagellar pocket, cytoplasmic vacuolisation FC: decrease in mitochondrial membrane potential, increase in permeability of the plasma membrane | ||
| Hydroxycopalic acid from |
| SEM: rounded cells, rupture of the plasma membrane with loss of the cell contents, alterations of the flagellar membrane TEM: mitochondrial damage, vesicles located in the flagellar pocket, abnormal chromatin condensation nuclear |
|
| Agathic, kaurenoic and pinifolic acids from |
| FC: depolarisation of the mitochondrial membrane potential, increase in plasma membrane permeability |
|
| Terpenes from |
| TEM: mitochondrial swelling, organelle disorganisation, membranous vacuole formation, concentric membrane structures FC: depolarisation of the mitochondrial potential, increase in plasma membrane permeability AS: lipid peroxidation |
|
| Copaiba oil from |
| FC: depolarisation of the mitochondrial potential AS: lipid peroxidation |
|
|
| TEM: swelling of the kinetoplast and chromatin condensation in both the nucleus and mitochondrion, disorganisation of the membranes |
SEM: scanning electron microscopy; TEM: transmission electron microscopy; FM: fluorescence microscopy; FC: flow cytometry; AS: spectrophotometric assay.
Fig. 1:mitochondrial swelling in trypanosomatids after the treatment with eupomatenoid-5. (A) Chemical structure of eupomatenoid-5, the neolignan isolated from Piper regnellii var. pallescens. (B) Untreated epimastigotes of Trypanosoma cruzi presenting typical elongated morphology of the mitochondrion. (C) Epimastigotes treated with eupomatenoid-5 showing intense mitochondrial swelling. (D) Untreated promastigotes of Leishmania amazonensis presenting a typical mitochondrion with normal kinetoplast. (E) Promastigotes treated with eupomatenoid-5 showing remarkable mitochondrial swelling in the kinetoplast region. (m) mitochondrion; (k) kinetoplast; (*) mitochondrial swelling. Bars: 1 μm.
Fig. 2:trypanosomatids show unique mitochondrion that is attractive for drug discovery. Major natural antitrypanosomatid compounds evaluated by our research group that cause changes in this organelle.